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Restoration of physiologic metabolic control is the ultimate
therapeutic goal for patients with diabetes but is diﬃcult
to achieve by means of medical therapy. Transplantation
of islets of Langerhans represents a viable therapeutic
option for patients with insulin-dependent diabetes. It is
currently oﬀered to patients with a brittle form of diabetes
and hypoglycemia unawareness. Current limitations of islet
transplantationincludescarcityofdeceaseddonorpancreata,
partially eﬀective islet isolation and puriﬁcation protocols,
need for life-long systemic immunosuppression, inadequate
implantation sites, lack of predictive tests, and noninvasive
graft monitoring protocols.
Great progress has been recorded in diﬀerent research
areas aimed at overcoming current limitations of islet cell
transplantation. These areas include stem cells technology,
xenotransplantation, development of novel immunosup-
pressive regimens, immune tolerance, immunoisolation pro-
tocols, alternative sites for islet implantation, immune mon-
itoring, and noninvasive imaging techniques. This special
issue was open to the scientiﬁc community working on
the development of beta-cell replacement. Of the several
papers received, ten received favorable peer reviews and were
selected for publication in this issue to cover speciﬁc topics
of general interest in this ﬁeld.
The paper by C. Jahansouz et al. provides a compre-
hensive and historical overview of beta-cell replacement
therapies. The paper by P. Chhabra and K. L. Brayman
reviews emerging clinical and preclinical approaches toward
enhancing the clinical outcome of islet cell transplantation
and includes aspects related to cytoprotection and immune
interventions. The paper by H. Wang et al. is focused on
importantcytoprotectivepathwayssuchascarbonmonoxide
and heme oxygenase-1 and their ability to enhance islet
cell viability and engraftment. The paper by X. Wang et al.
oﬀers a perspective on the B7-H4 co-stimulation pathway
and its potential toward enhancing immune regulation and
prolonging islet graft survival.
Recognizing the current limitations of human pan-
creas donation after brain death, alternative cellular-based
approaches are actively being explored to widen the clinical
application of beta-cell replacement therapies. The paper by
M. R. Hammerman provides interesting new experimental
data on porcine islet cell engraftment in xenogeneic recipi-
ents without immunosuppression. In his paper H. Noguchi
shares an overview of his experience with novel protocols
aimed at ameliorating pancreas preservation injury and
improving the yield and quality of islets obtained for trans-
plantation. I. Meivar-Levy et al. explore the use of hepatic
cells expressing albumin and mesenchymal properties that
have been engineered to produce insulin as an alternative
and potentially unlimited source of transplantable insulin-
producing cells. F. Carlotti et al. assess the important issue
of the pros and cons related to the translatability of results
obtained in rodent studies to humans when studying beta-
cell regeneration.
There are increasing eﬀorts aimed at developing novel
implantation sites for islet cells. The paper by D. Espes2 Journal of Transplantation
etal.describesthepromisingpropertiesofintramuscularsite
which makes of it a viable option for islet cell implantation.
P. Wang et al. review the important and rapidly evolving
ﬁeld in vivo islet imaging. The use of molecular imaging
techniques may be of invaluable assistance toward moni-
toring islet grafts as well as a tool to better understand the
physiopathological changes that occur after transplantation.
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